Fitusiran FDA Approval: A Closer Look at Hemophilia Treatment

Fitusiran is a first-in-class RNA-based therapy approved by the FDA for routine prophylaxis in people with hemophilia A or B, with or without inhibitors to clotting factor. Rather than replacing the missing clotting factor, fitusiran lowers a natural anticoagulant protein called antithrombin, tipping the hemostatic balance back toward more effective clot formation. In pivotal trials, it cut bleeding rates by roughly 80 to 90 percent compared with on-demand treatment, and about half to two-thirds of participants experienced zero treated bleeds during the study period. The road to approval, however, included a clinical hold after a patient death and a significant rethinking of how the drug should be dosed.

How Fitusiran Works

Traditional hemophilia treatment replaces what is missing. People with hemophilia A lack functional factor VIII; those with hemophilia B lack factor IX. Standard care involves infusing the missing factor, either on a regular schedule to prevent bleeds or on demand when bleeding occurs. Fitusiran takes an entirely different approach. It belongs to a newer category called non-factor therapies, which restore clotting balance through mechanisms that have nothing to do with directly replacing factor VIII or IX.¹

Fitusiran is a small interfering RNA, or siRNA, that silences the gene responsible for producing antithrombin in the liver. Antithrombin is one of the body’s built-in brakes on clotting. In a person without hemophilia, antithrombin keeps clot formation in check so that clots do not run away and block blood vessels. But in someone whose clotting cascade is already weakened by a missing factor, antithrombin can be an obstacle. By dialing down antithrombin production, fitusiran lets whatever residual clotting ability exists work more efficiently.² Early-phase work showed that reducing antithrombin levels by more than three-quarters from baseline could bring thrombin generation up to the lower end of the healthy range.³

This mechanism is agnostic to the type of hemophilia. Because it does not depend on factor VIII or factor IX at all, it works whether someone has hemophilia A or B. And because it sidesteps the clotting factors entirely, it also works in patients who have developed inhibitors, antibodies that neutralize infused clotting factor and make standard replacement therapy ineffective.

What the ATLAS Trials Showed

The FDA approval rested primarily on the ATLAS clinical trial program, a set of phase 3 studies that tested fitusiran in different hemophilia populations. Three randomized controlled trials formed the core evidence base, enrolling a combined total of over 300 participants.⁴

The ATLAS-INH trial focused on the hardest-to-treat group: people with hemophilia A or B who had developed inhibitors. Those randomized to fitusiran prophylaxis had a mean annualized bleeding rate of about 1.7, compared with 18.1 in the group receiving on-demand bypassing agents. That works out to roughly a 91 percent reduction. Two-thirds of the fitusiran group had zero treated bleeds during the study, compared with just one in twenty in the on-demand group.⁵

The ATLAS-A/B trial enrolled people with severe hemophilia A or B without inhibitors. Here, the fitusiran group had a mean annualized bleeding rate of about 3.1, versus 31.0 for on-demand clotting factor concentrates. About half the fitusiran group experienced no treated bleeds at all.⁶

A third trial, ATLAS-PPX, asked a tougher question: could fitusiran beat not just on-demand treatment, but existing prophylactic regimens with conventional clotting factor or bypassing agents? Participants who switched to fitusiran saw bleeding rates drop by about 80 percent compared with their prior prophylaxis, and roughly 63 percent had zero treated bleeds on fitusiran compared with 17 percent on their previous regimen.⁷ Joint bleeds and spontaneous bleeds both dropped substantially.

Taken together, these trials established that fitusiran prophylaxis dramatically reduces bleeding across different hemophilia populations, whether compared with no prophylaxis or with existing prophylactic strategies.

The Early Safety Scare and How Dosing Evolved

Fitusiran’s path to approval was not smooth. During earlier clinical development, a participant with hemophilia A in a phase 2 open-label extension study died from cerebral swelling. The FDA placed a clinical hold on the entire fitusiran program, halting all dosing. The hold was eventually lifted after the trial protocol was amended with new risk-mitigation measures, including clearer guidelines around dosing for the treatment of breakthrough bleeds during studies. The key concern was that lowering antithrombin too aggressively, especially in combination with bypassing agents or factor concentrates given to treat acute bleeds, could tip the balance too far toward clotting and trigger dangerous thrombotic events.

This safety signal reshaped the entire dosing strategy. The original fitusiran dose was a flat 80 milligrams once monthly. That was replaced by an antithrombin-based dose regimen that targets antithrombin activity levels of 15 to 35 percent. Instead of giving everyone the same dose, clinicians now start at a lower dose and adjust upward or downward based on each patient’s measured antithrombin level.⁸ The starting dose dropped to 50 milligrams every two months, with options to go as low as 20 milligrams every two months or up to 80 milligrams monthly depending on antithrombin levels. A newer 10-milligram dose option has since been introduced to help keep more patients within that target window and reduce the number of people who need to stop treatment because their antithrombin drops below the safety threshold.⁹

Under the newer dosing approach, thrombotic events have become uncommon. In the long-term extension study, confirmed or suspected thromboembolic events occurred in about 1.4 percent of participants on the antithrombin-based regimen, and none of those events were associated with antithrombin levels falling below 15 percent. All four patients who experienced thrombotic events had pre-existing clinical risk factors, and both of the postoperative venous events occurred after patients received clotting factor or bypassing agents at doses exceeding the recommended guidelines.⁸

Other Side Effects to Watch For

Thrombotic events get the most attention because they are the most dangerous, but the more common side effects are less dramatic. Across studies, liver enzyme elevations have been one of the most frequently observed issues, showing up in roughly one in five to one in four participants.¹⁰ In the long-term safety analysis, elevated liver enzymes (ALT increase) were the single most common adverse event, reported in about 29 percent of participants on the original dose regimen. Most elevations were mild or moderate, and several occurred in patients with a history of alcohol use. Only one participant on the newer dosing regimen had elevated liver enzymes severe enough to prompt discontinuation.¹¹

Gallbladder-related events have also been flagged, occurring in about 13 to 15 percent of participants. Other commonly reported side effects include headache, joint pain, injection-site redness, and upper respiratory infections.¹¹ None of these are unusual for an siRNA therapy that acts on the liver, but the liver enzyme monitoring and gallbladder surveillance add a layer of clinical attention that standard factor replacement does not require.

How Fitusiran Compares to Other Non-Factor Therapies

Fitusiran is not the only non-factor therapy available. Emicizumab, a bispecific antibody that mimics the function of factor VIII, was approved several years earlier and became a widely used prophylactic option for hemophilia A. Concizumab, which targets tissue factor pathway inhibitor, is another entrant in the non-factor space. Each of these drugs works through a different mechanism, but they share the advantage of being given subcutaneously rather than intravenously, and all aim to prevent bleeds rather than simply treat them.

An exploratory network meta-analysis that compared all three agents head-to-head (indirectly, since no single trial has randomized patients among all three) found no statistically significant differences in annualized bleeding rates between them. The comparisons all had wide confidence intervals, reflecting the inherent uncertainty of indirect comparisons across different trial designs and populations.¹²

What this means in practice is that the choice among these therapies is less about which one is “best” in a head-to-head bleeding comparison and more about individual patient factors. Emicizumab only works for hemophilia A, because it mimics factor VIII specifically. Fitusiran and concizumab, by targeting anticoagulant pathways rather than mimicking a specific factor, work for both hemophilia A and B. That distinction matters enormously for the roughly 15 to 20 percent of hemophilia patients who have type B. Before these newer agents, hemophilia B patients without inhibitors had factor IX replacement as essentially their only prophylactic option, with none of the non-factor convenience that hemophilia A patients had gained through emicizumab.

Why Inhibitors Change the Calculus

The development of inhibitors, antibodies that attack and neutralize infused clotting factor, is one of the most serious complications in hemophilia treatment. The risk is highest in people with severe hemophilia A who are being treated for the first time, and it depends on a mix of genetic and environmental factors including the specific mutation causing the hemophilia, ethnicity, family history, and treatment intensity.¹³

When inhibitors develop, standard factor replacement therapy becomes partially or completely ineffective. Patients are typically switched to bypassing agents, which work around the blocked step in the clotting cascade rather than directly replacing the missing factor. Bypassing agents are less predictable, more expensive, and less effective at preventing bleeds than standard factor replacement. The ATLAS-INH trial specifically targeted this population, and the roughly 91 percent reduction in bleeding with fitusiran compared to on-demand bypassing agents represents a transformative improvement for people who had limited options.⁵

For the meta-analysis that pooled the three ATLAS trials, patients with inhibitors showed a statistically significant reduction in all measured bleeding endpoints with fitusiran, including total bleeds, spontaneous bleeds, and joint bleeds.⁴ Joint bleeds are particularly important because repeated bleeding into joints is the primary driver of the chronic arthropathy that causes disability in people with hemophilia. Any therapy that can prevent joint bleeds in a population that previously had poor prophylactic options has long-term implications that go beyond bleeding counts.

What Dosing and Monitoring Look Like in Practice

One of the practical appeals of fitusiran is the dosing schedule. It is given as a subcutaneous injection, which patients or caregivers can administer at home, and the current regimen ranges from once every two months to once monthly depending on the individual’s antithrombin levels. Compare that with conventional factor replacement prophylaxis, which for hemophilia A often requires intravenous infusions several times per week. Even extended half-life factor products typically need infusions every one to two weeks. A once-monthly or once-every-two-months subcutaneous injection is a substantial reduction in treatment burden.

The trade-off is that fitusiran requires regular monitoring of antithrombin activity levels to keep them within the target range. If antithrombin drops too low, the risk of clotting goes up. If it stays too high, the drug may not provide adequate bleed protection. This is a fundamentally different kind of monitoring than what most hemophilia patients are used to. Factor replacement monitoring typically involves checking factor levels around infusions, and many patients can go long stretches without lab work. With fitusiran, antithrombin monitoring becomes a recurring part of care, and dose adjustments may happen over time as the body’s response to the drug changes or stabilizes.

The management of breakthrough bleeds while on fitusiran also requires careful coordination. If a patient on fitusiran needs factor concentrates or bypassing agents for an acute bleed or surgery, the combination of lowered antithrombin and exogenous clotting support can push the balance too far toward clotting. The early thrombotic events, including the fatal one during development, were linked to this exact scenario. Current guidelines specify lower doses and shorter durations of concurrent factor or bypassing agent use than would be standard in a patient not receiving fitusiran. Thrombin generation testing has been explored as a tool for guiding these co-administration decisions.¹⁴

Non-Factor Therapies and the Broader Shift in Hemophilia Care

Fitusiran’s approval is part of a larger transformation in how hemophilia is treated. For decades, the field revolved around replacing what was missing. The development of recombinant clotting factors, extended half-life products, and immune tolerance induction protocols for inhibitor patients all operated within the same basic paradigm: put the missing protein back in. Non-factor therapies break from that model entirely, targeting other parts of the clotting or anticoagulant system to achieve hemostatic balance by a different route.¹

This shift has practical consequences beyond individual drug efficacy. Non-factor therapies given subcutaneously on monthly or less frequent schedules reduce the venous access burden that has been a lifelong challenge for many hemophilia patients. Repeated intravenous infusions starting in early childhood can damage veins over time, and central venous access devices carry their own infection and thrombosis risks. A subcutaneous injection sidesteps all of that.

The landscape is also becoming more competitive, which benefits patients. With emicizumab, fitusiran, and concizumab all available or nearing availability, treatment centers have more tools to match therapy to the individual. A patient with hemophilia A and no inhibitors might do well on emicizumab. A patient with hemophilia B and inhibitors has fewer choices, and fitusiran fills a real gap there. Someone who cannot tolerate one agent’s side effect profile might switch to another. The evidence so far does not clearly favor one non-factor agent over the others in terms of bleeding reduction, so the decision often comes down to side effect tolerance, hemophilia type, inhibitor status, dosing preference, and what monitoring infrastructure is available at the treatment center.¹²

Gene therapy sits on the horizon as yet another approach, with the potential to provide a more durable correction of the underlying factor deficiency. But gene therapy availability remains limited, outcomes have been variable, and many patients are not eligible candidates. For the foreseeable future, non-factor therapies like fitusiran represent the most accessible leap forward, particularly for patients who have been underserved by conventional factor replacement or who face the added complication of inhibitors.